In metastatic breast cancer models, systemic pharmacologic inhibition of CXCR3 decreased lung metastasis12, 18, although the relative role of tumor- or myeloid-cell expressed CXCR3 could not be experimentally distinguished with this methodology. This evidence concerns the gene CXCR3 and breast carcinoma.